Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sonoma Pharmaceuticals (SNOA) has shared an update.
During the adjourned annual meeting on August 23, 2024, Sonoma Pharmaceuticals, Inc.’s stockholders made several key decisions including the election of two Class I directors, approval of executive compensation, and rejection of the company’s reincorporation from Delaware to Nevada. Additionally, they approved an increase in authorized shares, the 2024 Equity Incentive Plan, a reverse stock split, and the appointment of a new independent accounting firm. These decisions will significantly shape the company’s governance and financial strategy moving forward. A press release regarding the reverse stock split was subsequently issued.
See more insights into SNOA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects